In Brief: Exogen
This article was originally published in The Gray Sheet
Executive Summary
Exogen: Health Care Financing Administration denies Medicare reimbursement coverage for the firm's Sonic Accelerated Fracture Healing System, Exogen announces Aug. 23. The Piscataway, New Jersey firm says it is "disappointed" in HCFA's determination and plans "to aggressively pursue all avenues to reverse this decision." Exogen says it presented HCFA with "clinical and economic outcome data" on 105 Medicare patients treated with the system and reported a 94% healing rate, adding that it "estimates that a significant economic benefit well above the cost of the SAFHS therapy has been realized by these patients." The firm also reports that it has not recorded any revenues from Medicare sales...